{"id":2138,"date":"2025-06-04T14:05:09","date_gmt":"2025-06-04T14:05:09","guid":{"rendered":"https:\/\/leyton.majjane.agency\/ca\/post\/sred-for-bioscience-neurotechnology-and-psychedelics\/"},"modified":"2026-07-26T19:28:57","modified_gmt":"2026-07-26T17:28:57","slug":"sred-for-bioscience-neurotechnology-and-psychedelics","status":"publish","type":"article","link":"https:\/\/leyton.com\/ca\/en\/insights\/articles\/sred-for-bioscience-neurotechnology-and-psychedelics\/","title":{"rendered":"SR&ED for Bioscience: Neurotechnology and Psychedelics"},"content":{"rendered":"

Over the last decade, Canada <\/strong>has been establishing itself a premier hub for innovative research in psychedelic research and neurotechnology<\/strong><\/a>, holding immense potential for revolutionizing mental health<\/strong> and neurological treatment<\/strong>.<\/p>\n

For emerging firms eager to make strides in the domain, navigating the financial landscape to fund such cutting-edge research can prove to be challenging. <\/p>\n

By leveraging tax incentives, the Scientific Research and Experimental (SR&ED) program<\/strong><\/a> offers a strategic avenue to secure funding, allowing Canadian businesses to push the boundaries of innovation. <\/p>\n

As one of the leading and most generous research and development (R&D) tax incentive programs available globally<\/strong>, the SR&ED<\/a><\/strong> program provides tax credits<\/strong> to Canadian businesses that conduct R&D in various scientific domains, including psychedelic research and neurotechnology<\/strong>.<\/p>\n

These incentives can be claimed<\/strong> by enterprises of all sizes<\/strong>, from startups <\/strong>to large corporations<\/strong>, making it an essential tool for those looking to offset the costs of their innovative projects. <\/p>\n

Why do neurotechnology and psychedelics qualify for SR&ED?<\/h2>\n
<\/div>\n
\"brain<\/figure>\n
<\/div>\n

Due to the innovative <\/strong>and high-risk<\/strong>, high-reward nature<\/strong> of these scientific domains<\/strong>, neurotechnology and psychedelic research are poised to be highly attractive for receiving SR&ED <\/a><\/strong>credits. <\/p>\n

Aided by technological advancements in the domain of brain-computer<\/strong> interfaces, neurostimulation devices, and neuroimaging tools, significant innovations pushing the boundaries of current neuroscientific <\/strong>knowledge have been observed.<\/p>\n

These innovations often requiring substantial R&D investment<\/strong> with uncertain outcomes<\/strong>. Render them prime candidates for SR&ED<\/a><\/strong> credits designed to offset the risks<\/strong> associated with pioneering research.<\/p>\n

Concurrently, given the historical regulatory <\/strong>challenges and the emerging scientific evidence <\/strong>supporting the efficacy of psychedelics<\/strong>. Innovative research focusing on exploring novel therapeutic uses of psychedelic <\/a><\/strong>compounds for treating mental health disorders, aligns seamlessly with the SR&ED criteria. <\/p>\n

Recently, the Canadian government has been increasingly prioritizing mental health<\/strong>, neurological health,<\/strong> and the life sciences<\/a><\/strong> as key areas for investment. <\/p>\n

Operating at the intersection of these priorities, while aligning with national health agendas, the societal benefits<\/strong> of breakthroughs in these domains are substantial, rendering them attractive <\/strong>for SR&ED<\/strong> support.<\/p>\n

Furthermore, the complexity <\/strong>and the iterative nature<\/strong> of the research and development work<\/strong> involved with both neurotechnology <\/strong>and psychedelics<\/strong>. Such as developing new algorithms for brain data analysis<\/strong> or conducting clinical trials to assess the safety and efficacy of psychedelics, align well with the SR&ED<\/a><\/strong> program\u2019s emphasis on systematic investigation and experimentation. <\/p>\n

Lastly, due to its alignment with the SR&ED objective of supporting research with strong commercialization prospects<\/strong>. Firms with significant commercial interest<\/strong> in neurotechnology <\/strong>and psychedelics <\/strong>that innovate and bring new medical devices<\/strong>, therapies<\/strong>, and diagnostics <\/strong>to market, position themselves as premier candidates for receiving these credits. <\/p>\n

How to maximize Neurotechnology & Psychedelics SR&ED benefits? <\/h2>\n

To fully leverage SR&ED<\/strong> benefits, enterprises must understand the nuanced eligibility criteria <\/strong>and the types of activities that qualify<\/strong>.<\/p>\n

Here\u2019s how to postion your neurotechnology or psychedelics research project to maximize these benefits: <\/p>\n

Qualifying Activities <\/h3>\n

SR&ED credits apply to projects that aim to advance scientific knowledge<\/strong> or develop new <\/strong>or improved products <\/strong>or processes<\/strong>. For neurotechnology and psychedelics, this could include experimental development, applied research<\/strong>, and even some types of clinical trials.<\/p>\n

Furthermore, collaborative projects, such as those with academic institutions or other companies, can also qualify for SR&ED credits. <\/p>\n

Documentation is King <\/h3>\n

Keep detailed records<\/strong> of your research activities<\/strong>, including hypotheses, methodologies, and results. <\/p>\n

This documentation is crucial <\/strong>in demonstrating to the Canada Revenue Agency (CRA)<\/strong> that your work qualifies for SR&ED<\/strong> credits. <\/p>\n

Leverage SR&ED Expertise <\/h3>\n

Engaging with SR&ED<\/strong><\/a> consultants who specialize in your industry can streamline the application process. <\/p>\n

These experts can help identify all eligible expenditures, optimize your claim, and ensure compliance with CRA guidelines<\/strong>. <\/p>\n

In addition to SR&ED, by working with industry experts<\/strong>, Canadian businesses may also be able to leverage other tax incentives<\/strong> and grants<\/strong><\/a>, such as NIH R01, R21 and R33 grants, further reducing the financial burden of research and development. <\/p>\n

The Path Forward \u2013 Let\u2019s Talk! <\/h3>\n

For Canadian enterprises<\/strong> in the neurotechnology and psychedelics sector<\/strong>, the SR&ED program<\/strong> represents a unique opportunity to secure financial support and fuel innovation<\/strong>.<\/p>\n

By understanding the program’s nuances and strategically positioning your research activities. One can unlock substantial benefits <\/strong>that drive both scientific advancement <\/strong>and commercial success<\/strong>. <\/p>\n

The future of neurotechnology and psychedelics is promising, and with the right financial strategies, your company can be at the forefront of this exciting evolution. <\/p>\n

Explore our comprehensive financial solutions and maximize your R&D funding<\/a><\/strong>. <\/p>\n

The gateway to unlocking the full potential of your innovations awaits you. <\/p>\n

Take the leap today and secure your future success! <\/p>\n

<\/div>\n
\n
Book a meeting with a consultant!<\/a><\/div>\n<\/div>\n
<\/div>\n","protected":false},"excerpt":{"rendered":"

Over the last decade, Canada has been establishing itself a premier hub for innovative research in psychedelic research and neurotechnology, holding immense potential for revolutionizing mental health and neurological treatment. For emerging firms eager to make strides in the domain, navigating the financial landscape to fund such cutting-edge research can prove to be challenging. By […]<\/p>\n","protected":false},"author":1,"featured_media":2837,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[286,287,309,110,111],"tags":[363,232,385,114,2813,115,528],"expertise":[774],"class_list":["post-2138","article","type-article","status-publish","format-standard","has-post-thumbnail","hentry","category-biotech","category-medical-devices","category-pharma","category-sred","category-tax-credit","tag-biotechnology","tag-funding","tag-healthtech","tag-innovation-en","tag-neuroscience","tag-sred-en","tag-tax-credit","expertise-sred-tax-credits"],"acf":[],"yoast_head":"\nSR&ED for Bioscience: Neurotechnology and Psychedelics - Leyton Canada<\/title>\n<meta name=\"description\" content=\"Discover how Canadian neurotechnology and psychedelics companies can leverage SR&ED tax credits to fund innovative research in bioscience.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/leyton.com\/ca\/en\/insights\/articles\/sred-for-bioscience-neurotechnology-and-psychedelics\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"SR&ED for Bioscience: Neurotechnology and Psychedelics\" \/>\n<meta property=\"og:description\" content=\"Discover how Canadian neurotechnology and psychedelics companies can leverage SR&ED tax credits to fund innovative research in bioscience.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/leyton.com\/ca\/en\/insights\/articles\/sred-for-bioscience-neurotechnology-and-psychedelics\/\" \/>\n<meta property=\"og:site_name\" content=\"Leyton Canada\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-26T17:28:57+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/leyton.com\/wp-content\/blogs.dir\/3\/files\/2025\/05\/SRED-for-Bioscience.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1920\" \/>\n\t<meta property=\"og:image:height\" content=\"655\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/leyton.com\\\/ca\\\/en\\\/insights\\\/articles\\\/sred-for-bioscience-neurotechnology-and-psychedelics\\\/\",\"url\":\"https:\\\/\\\/leyton.com\\\/ca\\\/en\\\/insights\\\/articles\\\/sred-for-bioscience-neurotechnology-and-psychedelics\\\/\",\"name\":\"SR&ED for Bioscience: Neurotechnology and Psychedelics - Leyton Canada\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/leyton.com\\\/ca\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/leyton.com\\\/ca\\\/en\\\/insights\\\/articles\\\/sred-for-bioscience-neurotechnology-and-psychedelics\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/leyton.com\\\/ca\\\/en\\\/insights\\\/articles\\\/sred-for-bioscience-neurotechnology-and-psychedelics\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/leyton.com\\\/wp-content\\\/blogs.dir\\\/3\\\/files\\\/2025\\\/05\\\/SRED-for-Bioscience.jpg\",\"datePublished\":\"2025-06-04T14:05:09+00:00\",\"dateModified\":\"2026-07-26T17:28:57+00:00\",\"description\":\"Discover how Canadian neurotechnology and psychedelics companies can leverage SR&ED tax credits to fund innovative research in bioscience.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/leyton.com\\\/ca\\\/en\\\/insights\\\/articles\\\/sred-for-bioscience-neurotechnology-and-psychedelics\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/leyton.com\\\/ca\\\/en\\\/insights\\\/articles\\\/sred-for-bioscience-neurotechnology-and-psychedelics\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/leyton.com\\\/ca\\\/en\\\/insights\\\/articles\\\/sred-for-bioscience-neurotechnology-and-psychedelics\\\/#primaryimage\",\"url\":\"https:\\\/\\\/leyton.com\\\/wp-content\\\/blogs.dir\\\/3\\\/files\\\/2025\\\/05\\\/SRED-for-Bioscience.jpg\",\"contentUrl\":\"https:\\\/\\\/leyton.com\\\/wp-content\\\/blogs.dir\\\/3\\\/files\\\/2025\\\/05\\\/SRED-for-Bioscience.jpg\",\"width\":1920,\"height\":655},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/leyton.com\\\/ca\\\/en\\\/insights\\\/articles\\\/sred-for-bioscience-neurotechnology-and-psychedelics\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/leyton.com\\\/ca\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"SR&ED for Bioscience: Neurotechnology and Psychedelics\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/leyton.com\\\/ca\\\/#website\",\"url\":\"https:\\\/\\\/leyton.com\\\/ca\\\/\",\"name\":\"Leyton\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/leyton.com\\\/ca\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/leyton.com\\\/ca\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/leyton.com\\\/ca\\\/#organization\",\"name\":\"Leyton\",\"url\":\"https:\\\/\\\/leyton.com\\\/ca\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/leyton.com\\\/ca\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/leyton.com\\\/wp-content\\\/blogs.dir\\\/3\\\/files\\\/2026\\\/01\\\/logo.svg\",\"contentUrl\":\"https:\\\/\\\/leyton.com\\\/wp-content\\\/blogs.dir\\\/3\\\/files\\\/2026\\\/01\\\/logo.svg\",\"width\":108,\"height\":44,\"caption\":\"Leyton\"},\"image\":{\"@id\":\"https:\\\/\\\/leyton.com\\\/ca\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"SR&ED for Bioscience: Neurotechnology and Psychedelics - Leyton Canada","description":"Discover how Canadian neurotechnology and psychedelics companies can leverage SR&ED tax credits to fund innovative research in bioscience.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/leyton.com\/ca\/en\/insights\/articles\/sred-for-bioscience-neurotechnology-and-psychedelics\/","og_locale":"en_US","og_type":"article","og_title":"SR&ED for Bioscience: Neurotechnology and Psychedelics","og_description":"Discover how Canadian neurotechnology and psychedelics companies can leverage SR&ED tax credits to fund innovative research in bioscience.","og_url":"https:\/\/leyton.com\/ca\/en\/insights\/articles\/sred-for-bioscience-neurotechnology-and-psychedelics\/","og_site_name":"Leyton Canada","article_modified_time":"2026-07-26T17:28:57+00:00","og_image":[{"width":1920,"height":655,"url":"https:\/\/leyton.com\/wp-content\/blogs.dir\/3\/files\/2025\/05\/SRED-for-Bioscience.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/leyton.com\/ca\/en\/insights\/articles\/sred-for-bioscience-neurotechnology-and-psychedelics\/","url":"https:\/\/leyton.com\/ca\/en\/insights\/articles\/sred-for-bioscience-neurotechnology-and-psychedelics\/","name":"SR&ED for Bioscience: Neurotechnology and Psychedelics - Leyton Canada","isPartOf":{"@id":"https:\/\/leyton.com\/ca\/#website"},"primaryImageOfPage":{"@id":"https:\/\/leyton.com\/ca\/en\/insights\/articles\/sred-for-bioscience-neurotechnology-and-psychedelics\/#primaryimage"},"image":{"@id":"https:\/\/leyton.com\/ca\/en\/insights\/articles\/sred-for-bioscience-neurotechnology-and-psychedelics\/#primaryimage"},"thumbnailUrl":"https:\/\/leyton.com\/wp-content\/blogs.dir\/3\/files\/2025\/05\/SRED-for-Bioscience.jpg","datePublished":"2025-06-04T14:05:09+00:00","dateModified":"2026-07-26T17:28:57+00:00","description":"Discover how Canadian neurotechnology and psychedelics companies can leverage SR&ED tax credits to fund innovative research in bioscience.","breadcrumb":{"@id":"https:\/\/leyton.com\/ca\/en\/insights\/articles\/sred-for-bioscience-neurotechnology-and-psychedelics\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/leyton.com\/ca\/en\/insights\/articles\/sred-for-bioscience-neurotechnology-and-psychedelics\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/leyton.com\/ca\/en\/insights\/articles\/sred-for-bioscience-neurotechnology-and-psychedelics\/#primaryimage","url":"https:\/\/leyton.com\/wp-content\/blogs.dir\/3\/files\/2025\/05\/SRED-for-Bioscience.jpg","contentUrl":"https:\/\/leyton.com\/wp-content\/blogs.dir\/3\/files\/2025\/05\/SRED-for-Bioscience.jpg","width":1920,"height":655},{"@type":"BreadcrumbList","@id":"https:\/\/leyton.com\/ca\/en\/insights\/articles\/sred-for-bioscience-neurotechnology-and-psychedelics\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/leyton.com\/ca\/"},{"@type":"ListItem","position":2,"name":"SR&ED for Bioscience: Neurotechnology and Psychedelics"}]},{"@type":"WebSite","@id":"https:\/\/leyton.com\/ca\/#website","url":"https:\/\/leyton.com\/ca\/","name":"Leyton","description":"","publisher":{"@id":"https:\/\/leyton.com\/ca\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/leyton.com\/ca\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/leyton.com\/ca\/#organization","name":"Leyton","url":"https:\/\/leyton.com\/ca\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/leyton.com\/ca\/#\/schema\/logo\/image\/","url":"https:\/\/leyton.com\/wp-content\/blogs.dir\/3\/files\/2026\/01\/logo.svg","contentUrl":"https:\/\/leyton.com\/wp-content\/blogs.dir\/3\/files\/2026\/01\/logo.svg","width":108,"height":44,"caption":"Leyton"},"image":{"@id":"https:\/\/leyton.com\/ca\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/leyton.com\/ca\/wp-json\/wp\/v2\/article\/2138","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/leyton.com\/ca\/wp-json\/wp\/v2\/article"}],"about":[{"href":"https:\/\/leyton.com\/ca\/wp-json\/wp\/v2\/types\/article"}],"author":[{"embeddable":true,"href":"https:\/\/leyton.com\/ca\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/leyton.com\/ca\/wp-json\/wp\/v2\/comments?post=2138"}],"version-history":[{"count":4,"href":"https:\/\/leyton.com\/ca\/wp-json\/wp\/v2\/article\/2138\/revisions"}],"predecessor-version":[{"id":7533,"href":"https:\/\/leyton.com\/ca\/wp-json\/wp\/v2\/article\/2138\/revisions\/7533"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/leyton.com\/ca\/wp-json\/wp\/v2\/media\/2837"}],"wp:attachment":[{"href":"https:\/\/leyton.com\/ca\/wp-json\/wp\/v2\/media?parent=2138"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/leyton.com\/ca\/wp-json\/wp\/v2\/categories?post=2138"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/leyton.com\/ca\/wp-json\/wp\/v2\/tags?post=2138"},{"taxonomy":"expertise","embeddable":true,"href":"https:\/\/leyton.com\/ca\/wp-json\/wp\/v2\/expertise?post=2138"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}